Ursodeoxycholic Acid Treatment in Primary Biliary Cirrhosis Patients (Stage I-II): Thirteen Years Follow-up: Evaluation of Standard Versus High Dosage, a Randomized Open Controlled Trial
Gastroenterology, Hepatology & Digestive Disorders · 30.06.2026 · 9 (2)
DOI: 10.33425/2639-9334.1114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastroenterology, Hepatology & Digestive Disorders, online erschienen am 30.06.2026. Verfasst von Giulia Roda und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Ursodeoxycholic Acid (UDCA), at a dose of 13-15 mg/kg daily is the only recommended drug for patients with primary biliary cirrhosis (PBC). Recent meta-analysis point-out the need of a re-evaluation of the role of UDCA in PBC. One of the criticisms risen to UDCA therapy is the range of the dose (8-15 mg/Kg/day) since at this dosage UDCA doesn’t exceed 35-45 % of total biliary bile acids (BA). On the other hand, higher dosage (30 mg/Kg/day) of UDCA can produce up to 65-75% of biliary UDCA accumulation with a potentially higher activity for the higher enrichment of this poor detergent BA. The aim of our study is to evaluate the long-term effect (up to 12 years) of high dose UDCA on liver and bile biochemistry, and histology in a randomized open controlled study.
Methods
40 non icteric PBC patients (I-II stage) have been randomized to receive high (H-UDCA;30 mg\Kg\day: 17 female and 3 male) or conventional UDCA dose (m-UDCA,15 mg\Kg\day: 18 female, and 2 males). Clinical and biochemical evaluations were performed twice per years. Liver biopsy was performed at baseline and after 6 years of treatment.
Results
Serum liver enzymes (ALT, AST, y-GT, ALP) and bilirubin significantly decreased in patients treated with H-UDCA compared to m-UDCA. Patients who normalized all the serum liver enzymes tests were defined “responders”, while patients who normalized only three parameters were defined “partial responders”. The other cases were considered “non-responder”. Among patients receiving H-UDCA, 85,7% were “responders” and 14,3% were “partial responders”. Instead, in the m-UDCA group, “responder”, “partial responder” and “non-responder” were respectively 23%, 35% and 42% (p
Zitieren
APA
Roda, G., Azzaroli, F., Montagnani, M., Mazzella, G., Roda, A., Porru, E., & Roda, E. (2026). Ursodeoxycholic Acid Treatment in Primary Biliary Cirrhosis Patients (Stage I-II): Thirteen Years Follow-up: Evaluation of Standard Versus High Dosage, a Randomized Open Controlled Trial. Gastroenterology, Hepatology & Digestive Disorders, 9(2). https://doi.org/10.33425/2639-9334.1114
Vancouver
Roda G, Azzaroli F, Montagnani M, Mazzella G, Roda A, Porru E, et al. Ursodeoxycholic Acid Treatment in Primary Biliary Cirrhosis Patients (Stage I-II): Thirteen Years Follow-up: Evaluation of Standard Versus High Dosage, a Randomized Open Controlled Trial. Gastroenterology, Hepatology & Digestive Disorders. 2026;9(2). doi:10.33425/2639-9334.1114
BibTeX
@article{Roda2026,
author = {Roda, Giulia and Azzaroli, Francesco and Montagnani, Marco and Mazzella, Giuseppe and Roda, Aldo and Porru, Emanuele and Roda, Enrico},
title = {Ursodeoxycholic Acid Treatment in Primary Biliary Cirrhosis Patients (Stage I-II): Thirteen Years Follow-up: Evaluation of Standard Versus High Dosage, a Randomized Open Controlled Trial},
journal = {Gastroenterology, Hepatology & Digestive Disorders},
year = {2026},
volume = {9},
number = {2},
doi = {10.33425/2639-9334.1114}
}
EUVIMED